Simulations Plus Teams Up with the University of Health Sciences and Pharmacy in St. Louis to Secure New Grant Award from the U.S. FDA

Partnership will develop and validate unique in vitro/in silico models for oral cavity products

Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that, through a joint proposal with the St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis, it has been awarded a new funded cooperative agreement from the U.S. Food and Drug Administration (FDA) to establish novel in vitro/in silico models for the oral cavity route of administration in GastroPlus® to accelerate pharmaceutical research and regulatory assessment of innovative and generic drug products delivered intraorally.

For this award, researchers at the University of Health Sciences and Pharmacy in St. Louis will generate data for marketed buccal and sublingual products using both standard in vitro systems and the innovative Dynamic In Vitro Dissolution and Absorption Model (DIVDAM) designed in their labs. The team at Simulations Plus will apply these data sets, along with additional information provided by scientists at the FDA and partner companies within the consortium, to build and validate mechanistic in vitro/in vivo correlations (IVIVCs) via physiologically based biopharmaceutics (PBBM) / pharmacokinetic (PBPK) oral cavity models within GastroPlus.

“The current state-of-the-art Oral Cavity Compartmental Absorption and Transit™ (OCCAT™) module in GastroPlus – the only model of its kind for this administration route – was created several years ago in collaboration with a large pharmaceutical company using limited in vitro data,” said Dr. Viera Lukacova, chief scientist at Simulations Plus. “Using the novel database generated by the University of Health Sciences and Pharmacy in St. Louis, the improved machine learning and PBBM / PBPK models will provide a better characterization of formulation effects and enhance regulatory assessments for innovator and generic products.”

Under the cooperative agreement, FDA scientific and program staff will assist and participate in project activities in a partnership role with the St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis, Simulations Plus, and several leading pharmaceutical and generic drug companies. Drs. Haiying Zhou and Maxime Le Merdy will serve as project leads from Simulations Plus and contribute to various aspects of the award.

“We are excited to initiate this FDA-funded project in collaboration with our colleagues at Simulations Plus. The value of this partnership between academia and industry is that it has the potential to accelerate translation of innovative discoveries into tangible patient benefits,” said Dr. Giovanni Pauletti, Associate Dean for Graduate Studies, Gustavus & Henry Pfeiffer Chair, Department of Pharmaceutical and Administrative Sciences, and Professor of Biopharmaceutics & Pharmacokinetics, University of Health Sciences and Pharmacy in St. Louis. “Specifically, for this research project, we aim to develop a novel in vitro/in silico model that will facilitate greater access to safe and effective generic drug products designed for administration within the oral cavity.”

John DiBella, Lancaster division president, added: “To now enter our third funded collaboration with the FDA in 2020 is an amazing accomplishment and speaks to the relationships forged and the reputation earned. Like recent awards for the ocular and dermal delivery routes, Simulations Plus will own all intellectual property developed within the GastroPlus program, and updates will be integrated into future versions and made available to clients. We continue to invite future collaborations to drive advances to modeling and simulation science which benefit our entire user community and, most importantly, the patients that we serve.”

Funding for this collaboration is made possible by the Food and Drug Administration through grant 75F40120C00150. Views expressed in this press release do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. For more information, visit our website at

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

Follow us on Twitter | LinkedIn

View source version on


Simulations Plus Investor Relations
Ms. Renee Bouche

Hayden IR
Mr. Cameron Donahue

Source Article